European Medicines Agency

Doc. Ref. EMEA/348182/2009
P/123/2009

EUROPEAN MEDICINES AGENCY DECISION

of 12 June 2009

on the acceptance of a modification of an agreed Paediatric Investigation Plan for rosuvastatin calcium (EMEA-000022-PIP01-07-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

DISCLAIMER: This Decision does not entitle to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006, as amended.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 12 June 2009

on the acceptance of a modification of an agreed Paediatric Investigation Plan for rosuvastatin calcium (EMEA-000022-PIP01-07-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the decision P/76/2009 of the European Medicines Agency on 20 April 2009,

Having regard to the application submitted by AstraZeneca AB on 15 May 2009 under Article 22 of Regulation (EC) No 1901/2006 as amended proposing changes to the agreed Paediatric Investigation Plan,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 May 2009, in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to an agreed Paediatric Investigation Plan,

(2) It is therefore appropriate to adopt a Decision on the acceptance of changes to an agreed Paediatric Investigation Plan.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

Changes to the agreed Paediatric Investigation Plan for rosuvastatin calcium, film-coated tablets, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, are hereby accepted.

Article 2

This decision, that supersedes previous decision of the European Medicines Agency P/76/2009, is addressed to AstraZeneca AB, 151 85 Södertälje, Sweden.

Done at London, 12 June 2009

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref. EMEA/PDCO/337769/2009
EMEA-000022-PIP01-07-M02

OPINION OF THE PAEDIATRIC COMMITTEE ON THE ACCEPTANCE OF A MODIFICATION OF AN AGREED PAEDIATRIC INVESTIGATION PLAN

Scope of the application

Active substance(s):
Rosuvastatin calcium

(Invented) name:
Crestor and associated names

Condition(s):
Primary hypercholesterolaemia
Homozygous familial hypercholesterolaemia
Primary combined (mixed) dyslipidaemia
Prevention of cardiovascular events

Pharmaceutical form(s):
Film-coated tablets

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
AstraZeneca AB

Information about the authorised medicinal product:
See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, AstraZeneca AB submitted to the EMEA on 15 May 2009 an application for modification of the agreed paediatric investigation plan as set out in the EMEA decision P/76/2009 of 20 April 2009. The application for modification proposed changes.

The procedure started on 28 May 2009.

Scope of the modification

The modification concerned details of the measure to address long term follow-up of potential safety issues in relation to paediatric use.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to the changes proposed by the applicant regarding the measures of the paediatric investigation plan,

The Icelandic and the Norwegian Paediatric Committee members do agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex(es) and appendix.

London, 29 May 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN

A. CONDITION(S)

Primary hypercholesterolaemia
Homozygous familial hypercholesterolaemia
Primary combined (mixed) dyslipidaemia
Prevention of cardiovascular events

B. WAIVER

- **Condition**

Primary hypercholesterolaemia (including heterozygous hypercholesterolaemia)

The waiver applies to:

- Children from birth to less than 6 years
  for the film-coated tablet for oral use
  on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need in the specified subset(s).

- **Condition**

Homozygous familial hypercholesterolaemia

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age
  for the film-coated tablet for oral use
  on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need in the specified subset(s).

- **Condition**

Primary combined (mixed) dyslipidaemia

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age
  for the film-coated tablet for oral use
  on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

- **Condition**

Prevention of cardiovascular events

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age
  for the film-coated tablet for oral use
  on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit.

C. PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

Primary hypercholesterolaemia

- **PIP indication**

Treatment of primary hypercholesterolaemia

- **Subset(s) of the paediatric population concerned by the paediatric development**

From 6 years to less than 18 years

- **Formulation(s)**

Film-coated tablet for oral use; 5mg, 10mg, 20mg

- **Studies**

Area	Number of studies	Description
Quality		Not applicable.
Non-clinical	1	Pre- and post-natal developmental toxicity in rats from day 7 of gestation to day 22 of lactation.
Clinical	3	Double-blind, randomised, multi-centre, placebo-controlled trial to evaluate safety and efficacy of rosuvastatin calcium in children from 10 years to less than 18 years of age with heterozygous hypercholesterolemia. Multi-dose study to evaluate pharmacokinetics and safety of rosuvastatin calcium in children from 6 years to less than 14 years of age with hypercholesterolaemia. Double-blind, randomised, multi-centre, placebo-controlled study to evaluate safety and efficacy in children from 6 years to less than Tanner stage II with hypercholesterolemia including assessments of vascular changes.

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2010
Deferral for some or all studies contained in the paediatric investigation plan:	No

ANNEX II

INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

Invented name Name	**Strength**	**Pharmaceutical Form**	**Route of administration**
Crestor and associated names	5 mg, 10 mg, 20 mg, 40 mg	Film-coated tablet	Oral use